Barron's Take

The ride-hailing company launched a self-driving service in Dallas with Avride. And a Wall Street firm upgraded the stock to Buy.

The S&P 500 may need a crypto comeback to make a run at its record high.

The cryptocurrency’s decline is testing investor sentiment heading into the final month of the year.

The chip maker is still in the lead, but it may soon have company.

This isn’t a DeepSeek moment. It is much, much bigger.

The AI trade has a barometer. It might not be Nvidia.

Alphabet stock was rising with Wall Street and technology analysts generally positive about its new Gemini 3 artificial-intelligence model.

Berkshire’s CEO Warren Biffett, and Vice Chairman Charlie Munger talked about the power and probability of Alphabet back in 2017.

Shares of Booking and Expedia were both down by percentages in the mid-single digits on Monday afternoon.

The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.

Some of Wall Street’s biggest concerns will be tested this week.

You can’t short the maker of ChatGPT, but you can bet against the software company.

Bank of America came up with 16 names that investors should consider buying. Renaissance Macro threw out a couple of sector ideas, too.

CoreWeave, Nebius and peers such as IREN have surged this year on the back of multibillion-dollar contracts to provide AI computing capacity to large technology companies.

Industrial companies like Caterpillar and Rockwell Automation looked promising this earnings season.

SoftBank Group has decided to sell its stake in Nvidia in order to fuel an even bigger bet on OpenAI.

AI debt might be everyone’s problem.

iRhythm Technologies stock has doubled this year.

Can the market remain irrational longer than Michael Burry’s bet against it?

“We expect to invest aggressively to meet these needs,” Meta’s CFO said.

Another day, another AI-dominated market.

Big jobs cuts at the online retailer offer a glimpse into the future.

Small-cap healthcare and midsize consumer names are in the crosshairs. Investors need to be very careful.